Skip to content
Search

Latest Stories

'Sobering' study prompted Britain to toughen its COVID-19 approach

A crucial projection study that helped convince the British government to impose more stringent measures to contain COVID-19 painted a worst case picture of hundreds of thousands of deaths and a health service overwhelmed with severely sick patients.

In a sharp toughening of Britain's approach to the outbreak on Monday, Prime Minister Boris Johnson closed down social life in the world's fifth largest economy and advised those over 70 with underlying health problems to isolate.


The modelling study, by a team led by Neil Ferguson, a professor of mathematical biology at Imperial College London, used new data gathered from Italy where the infectious disease epidemic has surged in recent weeks.

Comparing the potential impact of the COVID-19 disease epidemic with the devastating flu outbreak of 1918, Ferguson's team said that with no mitigating measures at all, the outbreak could have caused more than half a million deaths in Britain and 2.2 million in the United States.

Even with the government's previous plan to control the outbreak - which involved home isolation of suspect cases but did not include restrictions on wider society - could have resulted in 250,000 people dying "and health systems ... being overwhelmed many times over," the study said.

With the measures outlined - including extreme social distancing and advice to avoid clubs, pubs and theatres - the epidemic's curve and peak could be flattened, the scientists said.

"This is going to place huge pressure on us as a society, and economically," said Azra Ghani, a professor of infectious disease epidemiology at Imperial who co-led the work with Ferguson.

Tim Colbourn, an expert in global health epidemiology at University College London said the projections in the study signalled "tough times ahead".

"The results are sobering," he said.

This study helped change the British government's position, according to those involved with the decision. The government said it had accelerated its plans on "the advice of the experts" and that the new measures had always been "part of the government's action plan".

"We continue to follow the science and act on the advice of the experts, which is that we are bringing in these more substantial measures slightly faster than we originally planned," the source said.

Johnson's government had been criticised by some public health experts who were concerned that Britain was not acting fast or forcefully enough to contain the spread of COVID-19 while other countries such as Italy, Spain and France were taking far more draconian lock-down measures.

But Peter Piot, director of the London School of Hygiene & Tropical Medicine and a specialist in viruses and infectious disease epidemics, said Britain's approach "is solidly evidence-informed" and "strikes a sound balance between managing the current public health crisis as well as the multiple and complex societal implications."

"In this unprecedented pandemic, caused by a virus we still know so little about, there is no one size fits all approach to controlling it," Piot said. "We should be open to adapt the response to an ever changing epidemic, and to rapidly evolving scientific understanding."

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less